News

The fiscal year 2026 Health and Human Services funding package includes several key health provisions championed by the CF community. 

The Five-Year Strategic Plan (5YSP) will focus the Foundation’s priorities across all areas of our mission: Cure, Care, and Community. 

The Cystic Fibrosis Foundation’s 2020–2024 strategic plan guided progress in CF research, care, and community support. As we look ahead to our next strategic plan, the Foundation is continuing to prioritize work that will help us reach our mission of helping people with CF live longer, fuller lives, and ultimately delivering a cure for all.

The Cystic Fibrosis Foundation mourns the passing of Doris F. Tulcin, co-founder of the Foundation and tireless advocate for everyone living with cystic fibrosis.

4D Molecular Therapeutics will use the funding to support a Phase 2 trial expansion and redosing.

The funding will support an expansion of an ongoing Phase 2 clinical trial.

Skenderasi will oversee the Foundation’s investment portfolio and lead long-term investment strategy

SNIPR plans to enhance phages — a type of virus that targets bacteria — to improve their ability to eliminate persistent Pseudomonas infections in people with cystic fibrosis.

The four recipients’ programs creatively support emotional and physical well-being in the CF community. 

The funding will support preclinical research focused on the nonsense mutation G542X